Résumé
OBJECTIVE:To observe therapeutic efficacy and safety of cefoperazone sodium and sulbactam sodium combined with Shenmai injection in the treatment of elderly stroke associated pneumonia(SAP). METHODS:A total of 84 SAP patients in Dazhou Municipal Central Hospital during Mar. 2016-Mar. 2017 were divided into control group(42 cases)and observation group (42 cases)according to random number table. Based on routine treatment,control group was additionally given Cefoperazone sodium and sulbactam sodium for injection 3 g added into 5% Glucose injection 100 mL,intravenously,twice a day;suitable antibiotics were selected according to the results of pathogenic examination and drug sensitivity test. Observation group was additionally given Shenmai injection 100 mL added into 5% Glucose injection 250 mL intravenously,once a day,on the basis of control group. Both groups were treated for consecutive 2 weeks. Clinical efficacies of 2 groups were observed,and the levels of T-lymphocyte subsets(CD4+,CD8+,CD4+/CD8+)and inflammatory markers(TNF-α,hs-CRP,PCT),length of hospital stay before and after treatment. The ADR was recorded. RESULTS:The total response rate(95.24%)and marked response rate (47.62%)of observation group were significantly higher than those of control group(83.33%,23.81%);length of hospital stay in observation group [(15.24±3.53)d] was significantly shorter than control group [(18.43±4.21)d],with statistical significance (P<0.05).After treatment,the levels of CD4+and CD4+/CD8+in 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group;the levels of CD8 +,TNF-α,hs-CRP and PCT in 2 groups were significantly lower than before treatment;the observation group was significantly lower than the control group,with statistical significance(P<0.05);there was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Based on routine treatment,cefoperazone sodium and sulbactam sodium combined with Shenmai injection treat SAP significantly,can effectively improve immune function, reduce inflammation level and shorten the length of hospital stay without increasing the occurrence of ADR.
Résumé
Objective To study the efficacy and safety of cefoperazone sodium and sulbactam sodium in treatment of patients with community acquired pneumonia.Methods 210 patients with community acquired pneumonia were randomly divided into two groups; 105 cases in treatment group (the patients were treated with cefoperazone sodium and sulbactam sodium), 105 cases in control group(the patients were treated with cefazolin).Both groups were treated for 7 days efficacy and safety of both groups were evaluated.Results The total effective rate was 90.48% in the treatment group and 80.00% in the control group,there were significant differences between the two groups in treatment effect rate (P <0.05).There are 3 and 2 cases in the control group and treatment group respectively has adverse effect,and there were no significant differences between the two groups' adverse effect(P>0.05).Conclusion Cefoperazone sodium and sulbactam sodium in treatment of community acquired pneumonia could obviously improve therapeutic efficacy,shorten the disease's develop course,and had a good clinical prospect.
Résumé
AIM and METHOD: To investigate the antibacterial activity (ED50value) of cefoperazone sodium and tazobactam sodium (4:0.5) in vivo using minor modified Karbers method, which will offer some important evidences for clinical trial and therapy. RESULTS: The ED50 value of cefoperazone sodium and tazobactam sodium (4:0.5) and Cefoperazone sodium and sulbactam sodium (1:1) in vivo protested against zymogenic staphylococcus aureus and Escherichia coli in mice infected by these bacteria were 92.0 mg·kg-1 and 3.4 mg·kg-1, 164.0 mg·kg-1 and 6.9 mg·kg-1, respectively, and 256.5 mg·kg1 and 38.9 mg·kg-1 in single composed compound of cefoperazone sodium, cefoperazone sodium and tazobactam sodium (4:0.5) in vivo had more potent antibacterial activity compared with cefoperazone sodium and sulbactam sodium (1:1) and single composed compound of cefoperazone sodium. The ED50 value of cefoperazone sodium and tazobactam sodium (4:0.5) protested against pseudomonas aeruginosa in mice infected was lower than that of Cefoperazone sodium and sulbactam sodium and single composed compound of cefoperazone sodium. CONCLUSION: Cefoperazone sodium and tazobactam sodium made in China has an markedly therapeutic effect on antibacterial activity protected against zymogenic staphylococcus aureus and Escherichia coli and pseudomonas aeruginosa in mice infected by these bacteria.
Résumé
AIM and METHOD To investigate the antibacterial activity (ED 50 value) of cefoperazonesodium and tazobactam sodium (4∶0 5) in vivo using minor modified Karbers method,which will offer some important evidences for clinical trial and therapy RESULTS The ED 50 value of cefoperazone sodium and tazobactam sodium(4∶0 5) and Cefoperazone sodium and sulbactam sodium (1∶1) in vivo protested against zymogenic staphylococcus aureus and Escherichia coli in mice infected by these bacteria were 92 0 mg?kg -1 and 3 4 mg?kg -1 ,164 0 mg?kg -1 and 6 9 mg?kg -1 ,respectively,and 256 5 mg?kg -1 and 38 9 mg?kg -1 in single composed compound of cefoperazone sodium,cefoperazone sodium and tazobactam sodium (4∶0 5) in vivo had more potent antibacterial activity compared with cefoperazone sodium and sulbactam sodium (1∶1) and single composed compound of cefoperazone sodium. The ED 50 value of cefoperazone sodium and tazobactam sodium (4∶0 5) protested against pseudomonas aeruginosa in mice infected was lower than that of Cefoperazone sodium and sulbactam sodium and single composed compound of cefoperazone sodium CONCLUSION Cefoperazone sodium and tazobactam sodium made in China has an markedly therapeutic effect on antibacterial activity protected against zymogenic staphylococcus aureus and Escherichia coli and pseudomonas aeruginosa in mice infected by these bacteria